Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALPN-202 + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- Vertex
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Davoceticept (ALPN-202) in combination with pembrolizumab is an investigational immunotherapy regimen for advanced solid tumors. ALPN-202 is an engineered Fc fusion protein that combines a CD80 variant immunoglobulin domain, aiming to simultaneously provide PD-L1-dependent CD28 costimulation and dual checkpoint inhibition of both PD-L1 and CTLA-4. Pembrolizumab is a well-established monoclonal antibody targeting PD-1. The combination was intended to enhance antitumor immunity through synergistic immune checkpoint and costimulatory modulation. The regimen was evaluated in clinical trials (e.g., NEON-2), but the studies were terminated early due to fatal immune-mediated cardiac toxicities[1][3][6][7].
- Other names
- ALPN-202 + Keytrudadavoceticept + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD28 (Cluster of Differentiation 28)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on ALPN-202 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALPN-202 + pembrolizumab.